Every week, somewhere in a hospital, a patient receives a blood cancer diagnosis that should have come months earlier. Not because their doctor failed them. Not because the technology did not exist. But because the diagnostic chain that should have caught it earlier was either under-resourced, undervalued, or simply not understood by the people making healthcare decisions.

I have worked in clinical laboratories in Nigeria and the United Kingdom for over eight years. The single most consistent gap I have observed across both systems is not equipment. It is the persistent underestimation of what laboratory science actually contributes to cancer outcomes.

Haematological malignancies, leukaemia, lymphoma, and myeloma do not announce themselves on scans. They live in the blood. They are detected through full blood counts, blood film examinations, coagulation studies, and immunophenotyping. These are laboratory procedures, performed by biomedical scientists, often before a patient has even seen an oncologist. When those procedures are delayed, deprioritised, or performed without adequate specialist oversight, the window for early intervention narrows sometimes irreversibly.

This is not a theoretical concern. It is what happens when laboratory staffing is treated as a back-office consideration rather than a frontline clinical priority.

In the UK, where I currently practise, haematology laboratories operate under rigorous accreditation frameworks that enforce quality at every stage of the diagnostic process. The system is far from perfect, but the architecture of accountability exists. In many Nigerian teaching hospitals, that architecture is still being built, and it is being built by dedicated scientists working under considerable pressure with considerable skill.

What both systems share, however, is a communication problem. Laboratory scientists are rarely in the room when healthcare policy is being shaped. We do not attend the press conferences. We do not feature in the hospital brochures. Yet the data that drives every cancer treatment decision pass through our hands first.

If African health systems are serious about improving cancer survival rates and the continent carries a disproportionate burden of late-stage diagnoses, investing in haematology laboratory capacity is not optional. It is foundational. That means training more specialists, accrediting more laboratories, and critically, giving laboratory scientists a seat at the policy table.

The science to detect blood cancer earlier already exists. The professionals to do it are already here, already trained, and already working.

The question is whether decision-makers are paying attention.

Ojo-Rowland Atinuke is an HCPC-registered biomedical scientist specialising in clinical haematology and blood transfusion science within the NHS. She holds an MSc in Public Health from Northumbria University, Newcastle.